![Bernd Seizinger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bernd Seizinger
Directeur/Membre du Conseil chez
APTOSE BIOSCIENCES INC.
Fortune : 1 M $ au 31/05/2026
Profil
Dr. Bernd R.
Seizinger is an Independent Director at Turbine Simulated Cell Technologies Ltd., an Independent Director at Aptose Biosciences, Inc., an Independent Director at BioInvent International AB, an Independent Director at Oncolytics Biotech, Inc., an Executive Chairman & Chief Executive Officer at CryptoMedix, Inc. and an Independent Director at Aprea Therapeutics, Inc. He is on the Board of Directors at Turbine Simulated Cell Technologies Ltd., Aptose Biosciences, Inc., BioInvent International AB, Oncolytics Biotech, Inc., Aprea Therapeutics AB, Aprea Therapeutics, Inc., TriMod Therapeutics Ltd., Karolinska Institutet and Oxford BioTherapeutics Ltd. Dr. Seizinger was previously employed as a Non-Executive Director by Bionor Pharma ASA, a Member-Supervisory Board by Agennix AG, an Independent Director by BioXell SpA, a President & Chief Executive Officer by GPC Biotech AG, a VP-Oncology Drug Discovery & Academic Alliances by Bristol-Myers Squibb Pharmaceutical Research Institute, an Associate Professor-Neuroscience by Harvard Medical School, a Director-Molecular Neuro-Oncology Laboratory by The General Hospital Corp., a Chief Scientific Officer & Executive VP by Oscient Pharmaceuticals Corp., and a Principal by Princeton University.
He also served on the board at Nykode Therapeutics ASA and Santhera Pharmaceuticals Holding AG.
He received his doctorate degree from the Max-Planck-Institute for Molecular Genetics and a doctorate degree from Ludwig-Maximilians-Universität München.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ONCOLYTICS BIOTECH INC. 0,48 % | 01/06/2026 | 566 991 ( 0,48 % ) | 589 671 $ | 31/05/2026 |
| 31/12/2024 | 66 000 ( 0,1 % ) | 236 601 $ | 31/05/2026 | |
| 31/12/2024 | 650 000 ( 0,2 % ) | 220 649 $ | 31/05/2026 | |
APREA THERAPEUTICS, INC. 0,36 % | 21/04/2026 | 44 730 ( 0,36 % ) | 39 944 $ | 31/05/2026 |
APTOSE BIOSCIENCES INC. 0,02 % | 23/02/2026 | 566 ( 0,02 % ) | 934 $ | 31/05/2026 |
Postes actifs de Bernd Seizinger
| Sociétés | Poste | Début |
|---|---|---|
| ONCOLYTICS BIOTECH INC. | Directeur/Membre du Conseil | 08/06/2015 |
| BIOINVENT INTERNATIONAL AB | Directeur/Membre du Conseil | 01/01/2018 |
| APREA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/01/2015 |
| APTOSE BIOSCIENCES INC. | Directeur/Membre du Conseil | 13/09/2022 |
CryptoMedix, Inc.
 CryptoMedix, Inc. BiotechnologyHealth Technology Develops immune therapeutics for cancer treatment | Directeur Général | - |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops antibody-based medicines for oncology | Directeur/Membre du Conseil | 14/12/2016 |
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Directeur/Membre du Conseil | - |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Directeur/Membre du Conseil | 01/01/2015 |
TriMod Therapeutics Ltd.
 TriMod Therapeutics Ltd. BiotechnologyHealth Technology Develops novel platform technologies to treat cancer and autoimmune diseases | Directeur/Membre du Conseil | 01/11/2011 |
| ░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Bernd Seizinger
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Bernd Seizinger
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
76
Relations au 1er degré
23
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 23 |
|---|---|
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Markets and sells products to community-based primary care physicians | Commercial Services |
Aptose Biosciences, Inc.
 Aptose Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Discovers, research and develops anticancer therapies with high safety profiles | Health Technology |
Oncolytics Biotech, Inc.
 Oncolytics Biotech, Inc. BiotechnologyHealth Technology Discovers and develops pharmaceutical products for the treatment of cancers | Health Technology |
BioXell SpA
 BioXell SpA BiotechnologyHealth Technology Manufactures drugs for inflammatory diseases | Health Technology |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops antibody-based medicines for oncology | Health Technology |
GPC Biotech AG
 GPC Biotech AG Miscellaneous Commercial ServicesCommercial Services Discovers, develops and commercializes new anticancer drugs | Commercial Services |
BioInvent International AB
 BioInvent International AB BiotechnologyHealth Technology Develops and manufactures immunomodulatory antibodies for cancer treatment | Health Technology |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services Functions as a non profit organization that operates general hospital | Health Services |
Karolinska Institutet
Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Santhera Pharmaceuticals Holding AG
 Santhera Pharmaceuticals Holding AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of neuromuscular diseases | Health Technology |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Max-Planck-Institute for Molecular Genetics
 Max-Planck-Institute for Molecular Genetics Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bristol-Myers Squibb Pharmaceutical Research Institute | |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Health Technology |
Nykode Therapeutics ASA
 Nykode Therapeutics ASA Pharmaceuticals: MajorHealth Technology Develops vaccines and immunotherapy against infectious diseases and cancer | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Agennix AG
 Agennix AG BiotechnologyHealth Technology Discovers, develops and commercializes new anti-cancer drugs | Health Technology |
Bionor Pharma ASA
 Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Manufactures nutritional supplements and vaccines | Health Technology |
TriMod Therapeutics Ltd.
TriMod Therapeutics Ltd. BiotechnologyHealth Technology Develops novel platform technologies to treat cancer and autoimmune diseases | Health Technology |
CryptoMedix, Inc.
CryptoMedix, Inc. BiotechnologyHealth Technology Develops immune therapeutics for cancer treatment | Health Technology |
Aprea Therapeutics, Inc.
 Aprea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel anticancer compounds | Health Technology |
Turbine Simulated Cell Technologies Ltd.
 Turbine Simulated Cell Technologies Ltd. Packaged SoftwareTechnology Services Provides AI solutions to understand oncology patients with simulated cells | Technology Services |
